Litcius/Paper detail

Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

Karim Fizazi, Michael J. Morris, Neal D. Shore, Kim N., Michael J. Crosby, Johann S. de Bono, Ken Herrmann, Guilhem Roubaud, James Nagarajah, Mark T. Fleming, Brian Lewis, Luke T. Nordquist, Natalie Carnahan, Samson Ghebremariam, Marianna Hertelendi, Daniel Castellano, Oliver Sartor

2025The Lancet Oncology10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstate cancerQuality of life (healthcare)CastrationOpen labelOncologyProstateInternal medicineClinical trialUrologyCancerHormoneNursingProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial | Litcius